COSTECH Integrated Repository

Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery

Show simple item record

dc.creator Ober, Courtney A.
dc.creator Kalombo, Lonji
dc.creator Swai, Hulda
dc.creator Gupta, Ram B.
dc.date 2019-10-16T06:52:04Z
dc.date 2019-10-16T06:52:04Z
dc.date 2013-02
dc.date.accessioned 2022-10-25T09:20:34Z
dc.date.available 2022-10-25T09:20:34Z
dc.identifier https://doi.org/10.1016/j.powtec.2012.04.057
dc.identifier http://dspace.nm-aist.ac.tz/handle/123456789/488
dc.identifier.uri http://hdl.handle.net/123456789/95050
dc.description Research Article published by Elsevier Volume 236
dc.description Rifampicin (RIF) is precipitated in the presence of inhalable lactose particles using a supercritical antisolvent-drug excipient mixing (SAS-DEM) technique to create RIF/lactose microparticle composites intended to improve the effectiveness of pulmonary tuberculosis treatments by increasing the respirable fraction of RIF. These RIF/lactose microparticle composites are prepared by dissolving RIF in a liquid solvent and spraying the solution into a high pressure vessel containing supercritical CO2 and suspended lactose particles. As the CO2 extracts the liquid solvent, RIF microparticles precipitate to form a microparticle composite mixture with the lactose particles. The effects of solvent, RIF concentration, and RIF to lactose loading are examined. The RIF/lactose microparticle composites are characterized for composition, particle size and surface morphology, crystallinity, thermal behavior, and physicochemical properties. By placing 1000 mg of lactose microfine in the vessel and varying the spraying time of 1 mg/mL and 5 mg/mL RIF in methanol solutions, RIF/lactose microparticle composites of 1.2%, 7.2%, 14.0%, and 25.7% RIF with relative standard deviations of 5.7%, 4.5%, 5.2%, and 2.3%, respectively, are prepared. Based on scanning electron microscopy, homogeneous RIF/lactose composites consisting of spherical particles less than 8 μm in diameter are produced. X-ray diffraction reveals that the SAS precipitation of RIF form I from methanol produces a polymorphic mixture of RIF form I and RIF dihydrate, due to trace water content in the solvent, while both RIF and lactose retain their individual crystalline structures during SAS-DEM processing. Based on differential scanning calorimetry RIF dihydrate converts to amorphous RIF upon heating. Fourier transform infrared spectroscopy demonstrates the absence of chemical interactions between the RIF and lactose proving a physical composite of the two is produced by the SAS-DEM process, and indicating that the therapeutic effectiveness of the drug should be unaffected.
dc.format application/pdf
dc.language en
dc.publisher Elsevier
dc.subject Dry powder inhaler
dc.subject Supercritical antisolvent
dc.title Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery
dc.type Article


Files in this item

Files Size Format View
JA_LiSBE_Abstract_2013.pdf 76.28Kb application/pdf View/Open

This item appears in the following Collection(s)

Show simple item record

Search COSTECH


Advanced Search

Browse

My Account